Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins | Zendy

Zeinab Sarem | Zendy; Christiane BumkeVogt | Zendy; Ayman M. Mahmoud | Zendy; Biruhalem Assefa | Zendy; Martin O. Weickert | Zendy; A. Adamidou | Zendy; V. Bähr | Zendy; Jan Frystyk | Zendy; Matthias Möhlig | Zendy; Joachim Spranger | Zendy; Stefanie Lieske | Zendy; Andreas L. Birkenfeld | Zendy; A. Pfeiffer | Zendy; Ayman M. Arafat | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins

Author(s) -

Zeinab Sarem,

Christiane BumkeVogt,

Ayman M. Mahmoud,

Biruhalem Assefa,

Martin O. Weickert,

A. Adamidou,

V. Bähr,

Jan Frystyk,

Matthias Möhlig,

Joachim Spranger,

Stefanie Lieske,

Andreas L. Birkenfeld,

A. Pfeiffer,

Ayman M. Arafat

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-00558

Subject(s) - glucagon , medicine , endocrinology , foxo1 , insulin , protein kinase b , growth factor , biology , insulin like growth factor , chemistry , signal transduction , receptor , biochemistry

Depending on its lipolytic activity, glucagon plays a promising role in obesity treatment. Glucagon-induced growth hormone (GH) release can promote its effect on lipid metabolism, although the underlying mechanisms have not been well-defined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research